MACCS: Multicenter Australian CE in Patients With Suspected Crohn's Disease Study
Launched by MEDTRONIC - MITG · Feb 12, 2007
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
In the past few years, capsule endoscopy has sparked renewed interest in the investigation of small bowel Crohn's disease. A PillCam™SB capsule (Given Imaging Ltd, Yoqneam, Israel) is an ingestible, disposable video camera that transmits high quality images of the small intestinal mucosa. This enables the small intestine to be readily accessible to physicians investigating for the presence of small bowel disorders such as Crohn's disease. It has been demonstrated that capsule endoscopy identifies Crohn's disease when other methods are not helpful. Diagnostic yields of 70% have been reported...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient will be 10 years and older
- • Patient suffers from abdominal pain and/or diarrhea for the last 6 weeks and/or expresses extra-intestinal manifestations of CD
- * Patient has at least one of the following over the preceding 6 months (plus symptoms suspicious of small bowel Crohn's Disease):
- • Positive inflammatory marker (ESR, CRP, thrombocytosis, leucocytosis, fecal lactoferrin, fecal α-1 antitrypsin)
- • Unexplained anemia,
- • Recurrent fever,
- • Weight loss (at least 10% of normal body weight in adults),
- • Hypoalbuminaemia (\<3.5 g/dL),
- • Gastro-intestinal bleeding,
- • Chronic perianal disease (fistula, fissure),
- • Abnormal white cell scan
- • Positive ASCA
- • First degree relative of a person suffering from IBD (only for subjects without known IBD),
- • Patient underwent standard evaluation that includes colonoscopy and attempted ileoscopy and also SBFT within six months prior to enrollment, which were non-diagnostic. Blood tests should have been done within one month of enrolment.
- • Patient or legal guardian agrees to sign the Informed Consent Form
- Exclusion Criteria:
- • Patients with indeterminate colitis where the purpose is only to make a definitive diagnosis and where the inclusion criteria are not otherwise met
- • Patient is known to suffer from intestinal obstruction (symptoms such as severe abdominal pain with accompanying nausea or vomiting)
- • Definite stricture seen on SBFT
- • Patient had suspected GI stricture, a Given® Patency capsule was administered and Patient did not pass the Patency capsule.
- • Patient has a pacemaker or other implanted electro-medical device
- • Patient has known history of small bowel Crohn's disease
- • Patient on treatment for active IBD
- • Patient with suspected celiac disease that has not been excluded
- • Patient on non-steroidal anti-inflammatory drugs including Aspirin, (twice weekly or higher) during the 3 months preceding enrolment
- • Patient is pregnant
- • Patient has any condition, which precludes compliance with study and/or device instructions, such as swallowing problems
- • Patient suffers from life threatening conditions
- • Patient is currently participating in another clinical study that may directly or indirectly affect the results of this study
About Medtronic Mitg
Medtronic - Minimally Invasive Therapies Group (MITG) is a leading global sponsor focused on advancing minimally invasive surgical techniques and technologies to improve patient outcomes and optimize healthcare delivery. Committed to innovation and excellence, MITG develops a range of products and solutions that enhance surgical precision and efficiency, catering to a diverse array of medical conditions. Through rigorous clinical trials and research initiatives, Medtronic MITG aims to drive evidence-based practices in healthcare, ensuring that patients benefit from the latest advancements in minimally invasive procedures.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parkville, Victoria, Australia
Herston, Queensland, Australia
Camperdown, New South Wales, Australia
Daw Park, South Australia, Australia
Box Hill, Victoria, Australia
Fitzroy, Victoria, Australia
Malvern, Victoria, Australia
Nedlands, Western Australia, Australia
Patients applied
Trial Officials
Warwick Selby, MD
Principal Investigator
Royal Prince Alfred Hospital, Sydney, Australia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials